Background
==========

In Europe, the estimated incidence of prostate cancer is 238,000 new cases with 85,000 deaths per year \[[@B1]\]. Radical prostatectomy is the most widely used treatment for localized prostate cancer. Unfortunately, local recurrences occur in up to one-third of the patients by 5 years after surgery. It is generally accepted that 30% (27--32%) of all patients by 10 years after surgery suffer biochemical relapse, defined as increasing serum prostate-specific antigen (PSA) levels \>0.2 ng/ml \[[@B2],[@B3]\]. PSA relapse exposes to a 34% risk of metastatic disease at 5 years. After metastatic relapse, median survival is 5 years \[[@B4]\].

\"Salvage\" radiotherapy (RT) to the prostate bed for biochemical relapse achieved biochemical control in 10--66% of the patients at 5 years \[[@B5],[@B6]\]. PSA failure after prostatectomy could reflect local relapse or metastatic disease. At present, modern imaging techniques lack the sensitivity to differentiate between these two types of relapse. Identification of the best candidates for RT should be based on factors predictive for local relapse. Numbers of positive margins, low Gleason score and/or long PSA-doubling time have been proposed to select patients for RT, but they are still discussed \[[@B7]\].

In this study, we evaluated RT efficacy and determine prognostic factors identifying patients who may benefit from salvage RT.

Methods
=======

We reviewed the records of 59 patients who underwent RT between 1990 and 2003 for biochemical relapse of prostate cancer initially treated with radical prostatectomy. All patients had persistent or rising PSA \>0.20 ng/ml at some time after surgery. None had imaging (bone scan and/or abdominal-pelvic computed tomography (CT) Scan) or clinical evidence of metastases at the time of the biochemical relapse.

A number of potential predictive factors were recorded: initial PSA (before surgery); age at the time of the surgery; T stage; margin status (6 sides); seminal vesicle involvement or extracapsular invasion; surgical Gleason score; perineural invasion; PSA nadir after surgery; PSA-doubling time (PSA DT) between surgery and RT calculated as follows: Ln 2 × (*t2*- *t1*)/\[Ln (PSA t2) - Ln (PSA t1)\] \[[@B8]\]; PSA before RT (preRT PSA) and interval between surgery and RT.

RT delivered to the prostate bed a median of 66 Gy in 2.2 Gy daily fractions, four days per week, with 18 MV photon beams. Between 1990 and 1998, classical 2D RT was administered using a four-field box technique to 22 (37.3%) patients with fields of 10 cm × 10 cm shaped to protect small bowel, portions of the bladder and posterior rectal wall. The fields encompassed the prostatic/seminal vesicle bed and periprostatic tissues. Pelvic lymph nodes were not irradiated. After 1998, conformational 3D RT was adopted to define optimally the clinical target volume (CTV) and organs at risk (bladder and rectum). CTV included the prostatic/seminal bed, with a security margin to encompass subclinical disease in the periprostatic area. The planning target volume (PTV) was defined by extending the CTV 0.5 cm posteriorly and 1 cm in all other directions. No elective nodal irradiation was performed. Dose Volume Histograms were performed to decrease the dose at organs at risk. Treatment-related toxicity was graded according to the Radiation Therapy Oncology Group (RTOG) criteria \[[@B9]\] and the Expanded Prostate-cancer Index Composite (EPIC) score for urinary incontinence \[[@B10]\].

After radiation, patients were followed every 6 months by a radiation oncologist and a urologist with physical examination and PSA analysis. Imaging to exclude metastastic disease was performed at the physician\'s discretion, as was the prescription of hormone therapy for biochemical or clinical failure after RT. The interval between surgery and hormone therapy after RT failure was also recorded.

Biochemical failure after salvage RT was defined as an increase of the serum PSA value \>0.2 ng/ml confimed by a second elevation.

Clinical failure was defined as evidence of clinical, sonographic, radiographic, or scintigraphic recurrence. The primary end point was biochemical relapse or introduction of hormone therapy before the criteria of PSA recurrence or clinical failure before biochemical relapse were met.

The other end points were overall and specific survival rates.

Statistical analysis
--------------------

Survival curves were plotted using the Kaplan-Meier method. Survival rates were calculated from the last day of RT. The date of failure was defined at the time of the biochemical failure.

Patients who biochemically had no evidence of disease (bNED) were censured at the time of last follow-up.

Univariate and multivariate analysis using a Cox proportional hazards regression analysis were conducted to identify significant predictors of biochemical outcome for several clinical and pathological factors: pre surgery PSA; Gleason score; high-grade histological differentiation (4 or 5); extra prostatic extension (capsule or seminal vesicle invasion); positive surgical margin(s); ≥3 positive surgical margins; lymphovascular invasion; short PSA DT ≤12 months; persistently high PSA after surgery (\>0.2 ng/ml); preRT PSA ≥0.5, ≥1 or ≥2 ng/ml; surgery-RT interval; duration of RT; classical 2D or 3D RT.

For all analyses, the level of significance was set at 0.05.

Statistical analysis was performed using Statview software.

Results
=======

Patient characteristics
-----------------------

Patient and tumor characteristics are reported in Table [1](#T1){ref-type="table"}. Fifty-nine patients were treated within a 13-year interval. It should be noted that 11 (18.6%) patients had no lymph-node dissection at the time of radical prostatectomy and did not receive any lymph-node irradiation at the time of RT. One (2%) patient had a nodal involvement at the time of RT. Seven patients (12%) received short-term (≤6 months) hormonetherapy, with Luteinizing Hormone Releasing Hormone agonist, after surgery, at the urologist\'s discretion.

###### 

Characteristics of the 59 men who underwent RT for PSA relapse after radical prostatectomy

  Characteristic patients, n                      Values
  ----------------------------------------------- ---------------------
  Age, median \[range\]                           62 \[46-76\] years
  Preoperative PSA, median \[range\]              16.7 \[1-60\] ng/ml
  pTNM stage, n (%)                               
   pT2a                                           2 (3.4)
   pT2b                                           1 (1.7)
   pT2c                                           22 (37.3)
   pT3a                                           20 (33.9)
   pT3b                                           14 (23.7)
   pN^-^                                          47 (79.7)
   pN^+^                                          1 (1.7)
   pNx                                            11 (18.6)
  Gleason score, n (%)                            
   3--6                                           12 (20.3)
   7\*                                            30 (50.9)
    3+4                                           13 (23.6)
    4+3                                           13 (23.6)
   8                                              7 (11.9)
   9                                              10 (16.9)
  Positive surgical margins†, n (%)               35/58 (60.3)
   Minimal \<3                                    19/34 (55.9)
   Extensive ≥3                                   15/34 (44.1)
  Perineural invasion, n (%)                      40/46 (87)
  Detectable PSA after surgery, n (%)             12 (20.3)
  PSA rise after postsurgical negativity, n (%)   47 (79.7)
  PSA doubling time, median                       12.9 months
  PSA nadir preRT, median                         0.4 ng/ml
  PSA level preRT, median                         1.43 ng/ml
  Surgery to RT interval, median                  26 months

\* Score composition not detailed for 4 patients.

Thirty-five patients had positive margins but no mention of margin status was made in one patient\'s report.

RT was delivered to 80% of the patients because of a rising PSA levels after postoperative negativity and for persistently high PSA after surgery for the remaining 20%. 3D and 2D salvage RT was performed in 63% and 37% of the patients, respectively. The median RT dose delivered was 66 Gy (59.4--70.4) in a mean of 60 days.

Survival and bDFS
-----------------

Median follow-up was 38 months after completing RT. At 3 years, the overall and specific survival rates were 93% and 100% respectively. The estimated 5-year overall survival rate was 87% and specific survival was 96%.

bDFS at 3 years was 56.1%. The estimated 5-year bDFS was 41.2% (Figure [1](#F1){ref-type="fig"}).

![bDFS after the end of RT according to PSA \>0.2 ng/ml definition.](1471-2407-8-26-1){#F1}

Prognostic factors for bDFS
---------------------------

Biochemical control was analyzed using different preRT PSA thresholds (from \<0.5 to ≥2 ng/ml) (Figure [2](#F2){ref-type="fig"}): patients with preRT PSA \<0.5 or \[0.5--1\]ng/ml had comparable bDFS rates ≈70% while those with PSA of \[1--2\] or ≥2 ng/ml had ≈30% bDFS at 3 years. The bDFS rates for these different PSA thresholds were significantly different (p = 0.008). PreRT PSA of 1 ng/ml was the most significant threshold that could distinguish patients with good or bad biochemical control after RT: PSA \<1 ng/ml was associated with a 3-year bDFS of 68.3% compared to 30.1% for PSA ≥1 ng/ml (p = 0.0006) (Figure [3](#F3){ref-type="fig"}).

![**Comparisons of bDFS after the end of RT according to different preRT PSA thresholds**. PSA \< 0.5 ng/ml(○) vs. \[0.5--1\] ng/ml(□) vs. \[1--2\] ng/ml(Δ) vs. ≥2 ng/ml(◇).](1471-2407-8-26-2){#F2}

![**Comparison of bDFS after the end of RT according to 1 ng/ml preRT PSA threshold**. PSA ≥1 ng/ml(○) vs. \<1 ng/ml(□).](1471-2407-8-26-3){#F3}

PreRT PSA ≥1 (*p*= 0.001) or 2 ng/ml (p = 0.04) and not Gleason score or margin status, in particular, were associated with poor 3-year bDFS outcome (Table [2](#T2){ref-type="table"}). Multivariate analysis retained only preRT PSA ≥1 ng/ml as independently predictive of biochemical failure.

###### 

Prognostic factors of bDFS after salvage RT at 3 years (PSA \> 0.2 ng/ml definition), univariate analysis

                                     3-year bDFS (%)          
  ---------------------------------- ----------------- ------ ---------
  Criterion                          Yes               No     p-value
                                                              
  Presurgical PSA ≥10                58.2              48.2   0.8
  Gleason score ≥8                   40.3              65.2   0.2
  High grade (≥4)                    52.2              87.5   0.3
   pT3                               46.9              69.2   0.08
   pT3b                              41.7              60.7   0.2
  Positive margin(s)                 47.7              61.4   0.3
  ≥3 positive margins                58.3              58.8   0.7
  Perineural invasion                48.3              83.3   0.8
  PSA DT ≤12 months                  58.8              51.9   0.8
  No PSA negativity                  48.6              58.2   0.2
  PreRT PSA ≥2 ng/ml                 33                60.9   0.04
  PreRT PSA ≥1 ng/ml                 30.1              68.3   0.001
  Surgery-RT interval (≤12 months)   36.6              54.8   0.4
  RT duration (≥60 days)             54                57.5   1.0
  Classical 2D RT                    70                45.7   0.2

PSA: Prostate specific antigen; DT: doubling time; RT: radiotherapy.

Treatment tolerance
-------------------

Late rectal toxicity (grade ≥2) was seen in seven patients treated with 2D RT (2 grade 3 and 2 grade 4) versus 8 with 3D RT (1 grade 3 and 0 grade 4).

Severe (grade ≥2) late urinary tract complications (stricture, hematuria) were observed in 3 patients who received 2D RT versus 1 given 3D RT, with 1 grade 3 and 0 grade 4 for each technique. Urinary incontinence (EPIC grade ≥2) developed in 2 patients given 2D RT and 4 with 3D RT.

Discussion
==========

We obtained a 3- and 5-year bDFS of 56.1% and 41.2% respectively, which are comparable to most of those previously reported for prostate cancer patients given RT after prostatectomy \[[@B11]-[@B31]\] (Table [3](#T3){ref-type="table"}).

###### 

Published series of salvage radiotherapy for biochemical failure after radical prostatectomy

  Investigator          Year of publication   Patients (n)   Median Follow-up (months)   Freedom from Biochemical Relapse
  --------------------- --------------------- -------------- --------------------------- ----------------------------------
  Anscher \[11\]        2000                  89             48                          50% at 4 years
  Peschel \[12\]        2000                  39             \-                          27% at 3 years
  Pisansky \[13\]       2000                  166            52                          46% at 5 years
  Catton \[14\]         2001                  59             44                          48% at 3 years
  Koppie \[15\]         2001                  67             36                          44% at 3 years
  Leventis \[16\]       2001                  49             29                          43% at 3 years
  Vanuytsel \[17\]      2001                  53             36                          46% at 3 years
  Chawla \[18\]         2002                  54             45                          35% at 5 years
  De la Taille \[19\]   2002                  52             28                          51% at 3 years
  Do \[20\]             2002                  73             87                          45% at 10 years
  Kalapurakal \[21\]    2002                  41             31                          57% at 5 years
  Song \[22\]           2002                  61             36                          39% at 4 years
  Liauw \[23\]          2003                  51             46                          56% at 3 years
  Peyromaure \[24\]     2003                  62             44                          42% at 5 years
  Taylor \[25\]         2003                  44             35                          66% at 5 years
  Mc Donald \[26\]      2004                  102            50                          38% at 5 years
  Stephenson \[27\]     2004                  501            45                          50% at 45 months
  Patel \[28\]          2005                  48             16                          62.5% at 16 months
  Buskirk \[29\]        2006                  368            60                          46% at 5 years
  Neuhof \[30\]         2007                  171            39                          35% at 5 years
  Stockdale \[31\]      2007                  32             30                          56% at 30 months
  Current study         \-                    59             38                          56% at 3 years

Poorer prognoses, in terms of bDFS after RT, were previously associated with mainly: higher preRT PSA values, high-grade disease, and seminal vesicle involvement \[[@B13]-[@B27]\]. Indeed, for our 59 patients, preRT PSA was associated with biochemical relapse after RT.

High preRT PSA was associated with poor biochemical control after RT regardless of the biochemical definition used. This observation is consistent with the previously reported finding that preRT PSA was the most frequently selected factor predictive of bDFS \[[@B5]-[@B31]\]. Those authors described poorer prognoses associated with higher PSA values before RT using thresholds ranging from 0.4 to 2 ng/ml. An ASTRO consensus panel recommended that RT be delivered before the PSA level reaches 1.5 ng/ml \[[@B32]\]. For our patients with a preRT PSA \<1 ng/ml, the 3-year bDFS was significantly higher than for those with a PSA ≥1 ng/ml (70 vs 30% respectively). We analyzed 3-year bDFS as a function of different preRT PSA thresholds: rates declined as PSA concentrations increased from \<0.5 (66.4%) to ≥2 ng/ml (only 33%). These significantly different rates (*p*= 0.008) are strong arguments supporting early treatment after biochemical relapse. We think that, in the setting of RT, the earlier the better. When biochemical failure is confirmed, and a sufficient number of factors suggestive of local relapse are present, patients should be irradiated without waiting for PSA to reach 1 or 1.5 ng/ml.

Recently, the randomized EORTC 22911 study demonstrated significant improvement for adjuvant RT vs salvage RT in terms of bDFS and clinical local control at 5 years but not for overall survival \[[@B33]\]. Similarly, adjuvant RT significantly increased bDFS vs observation in the ARO 96-02 and the SWOG 8794 studies \[[@B34],[@B35]\]. But adjuvant RT based only on unfavorable histological prognostic features (positive surgical margins, seminal vesicle involvement or extra capsular effraction) would expose some of these patients to over treatment with the risk of incontinence and urethral stricture resulting from the accumulation of the two treatments. Indeed 40--50% of the patients with positive surgical margins would develop biochemical relapses at 5-years \[[@B36],[@B37]\]. To conclude definitively, we should compare adjuvant radiotherapy vs early salvage radiotherapy: GETUG and RADICALS ongoing trials will try to answer to this question.

Gleason score and high grade prostate cancer was associated with poor biochemical outcome in previous reported studies \[[@B19]-[@B30]\]. However, we did not find any significant bDFS difference for patients with a low (≤6) or high (≥7) Gleason scores. Seminal vesicle involvement or margin status was also previously associated with poorer outcome.

In this study, we did not observe any difference in terms of incontinence (grade ≥2) according to EPIC score or rectal toxicity (grade ≥2) between salvage 3D and 2D RT. Urinary tract toxicities (stricture, hematuria) were also similar for the two techniques, with very low frequencies in both groups which is consistent with the MSKCC experience, in which adjuvant/salvage 3D RT was associated with 5% grade ≥2 toxicity \[[@B38]\].

Conclusion
==========

Salvage RT is an effective treatment after radical prostatectomy. bDFS 3- and 5-years after salvage RT were 56% and 41%, respectively. RT was well tolerated in terms of urinary toxicity, especially with 3D RT. PreRT PSA was the most powerful prognostic of bDFS before RT delivery and surpassed all other factors evaluated. To increase its efficacy, RT should be given earlier after biochemical relapse, ideally when preRT PSA \<1 ng/ml, to obtain the best biochemical control.
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